查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138406

2022-2029 年註意力缺陷多動障礙的全球市場

Global Attention-Deficit Hyperactivity Disorder Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

增加獲得用於治療精神疾病的健康保險的機會，並增加多動症的患病率

由於獲得心理健康治療的健康保險的機會增加，預計市場將增長。

健康保險是指針對未來手術或醫療費用的保險。這是一份合同，個人或一群人通過該合同為其健康保險支付稱為預購保費的費用。根據保險類型的不同，被保險人自掏腰包支付醫療費用並由保險公司報銷，或者保險公司直接向服務提供商付款。來自全國心理健康調查 (NMHS) 的數據顯示，在低收入、就業有限和教育水平低的家庭中，精神障礙明顯更高，因此更容易患上精神障礙。同時，這些相同的因素限制了獲得和使用精神衛生服務。

預計 ADHD 患病率的上升將推動市場增長。

多動症的患病率在全球範圍內差異很大，從低至 1% 到接近 20% 不等，具體取決於所使用的診斷標準和評估工具。據估計，多動症的全球患病率為 5.3%，是兒童中最常見的精神障礙。 ADHD（注意力缺陷多動障礙）佔因殘疾而損失的總年數的 0.06%，佔所有死亡人數的 0.02%。多動症造成的大部分負擔發生在兒童時期。在早期干預和治療方面，需要提請決策者註意多動症造成的負擔的嚴重程度。

注意缺陷多動障礙 (ADHD) 是兒童和青春期最常見的神經發育障礙，影響所有學齡兒童和青少年的 2.2-17.8%。兒童多動症與廣泛的發育障礙有關，包括對學習或執行功能的控制有限，以及社交技能的全面損害。

與 ADHD 藥物相關的副作用預計會阻礙市場增長。

雖然興奮劑在減輕 ADHD 症狀方面非常有效，但一些兒童會出現令人不快甚至有害的副作用。如果副作用成為問題，醫生可能會嘗試改變您孩子服用的藥物量、給藥方式或類型。目標是了解什麼是有效的，同時盡量減少副作用。我很難入睡，因為睡前太刺激了，我經常在電腦上做一些事情來讓自己平靜下來。如果藥物失效，多動症可能會讓他們保持清醒。

另一種 ADHD 藥物阿托西汀 (Straterra) 雖然不是興奮劑，但與成人心律不齊有關。 FDA 建議有這些問題歷史的人遠離他人。多動症藥物可能與一些精神問題有關，但這種情況很少見。例如，有些人報告了攻擊性和敵意等行為問題。相比之下，其他人已經出現了雙相情感障礙的症狀。 FDA 還警告說，興奮劑 ADHD 藥物導致幻覺、抑鬱和偏執狂等精神病症狀的風險很小。

COVID-19 影響分析

在 COVID-19 大流行期間，多項協議影響了醫療實踐。與這種流行病相關的注意力缺陷多動障礙 (ADHD) 問題的診斷和監測程序受到了影響。由於存在 COVID-19 的風險，人們害怕尋求治療 ADHD 或購買藥物，這對注意力缺陷多動障礙 (ADHD) 市場產生了影響。

行業分析

注意力缺陷多動障礙市場根據各種行業因素（包括未滿足的需求、定價分析、供應鏈分析和監管分析）對市場進行了深入分析。

全球注意力缺陷多動障礙市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁結構。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按藥物類型劃分的市場細分
  • 按年齡組劃分的市場細分
  • 按分銷渠道劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 增加獲得用於治療精神疾病的醫療保險的機會
      • 注意力缺陷多動障礙 (ADHD) 市場因注意力缺陷多動障礙 (ADHD) 發病率上升而擴大
    • 限制因素
      • 與 ADHD 藥物相關的副作用正在阻礙注意力缺陷多動障礙 (ADHD) 市場。
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 流行病學分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按藥物類型

  • 興奮劑
  • 無刺激性

第 8 章年齡組

  • 童年和青春期
  • 成人

第 9 章分銷渠道

  • 零售藥房
  • 電子商務

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表
  • 擁有顛覆性技術的公司名單
  • 創業公司名單

第 12 章公司簡介

  • Supernus Pharmaceuticals, Inc.
    • 公司概況
    • 產品組合和內容
    • 主要亮點
    • 財務摘要
  • Pfizer Inc
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Mallinckrodt Pharmaceuticals
  • Johnson & Johnson
  • Hisamitsu Pharmaceutical Co., Inc.,
  • Chongqing Fujin Biology Medical Company
  • Wanbang Medical Company LIST NOT EXHAUSTIVE

第13章 DataM

簡介目錄
Product Code: DMPH3819

Market Oveview

Attention-Deficit Hyperactivity Disorder Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.0% during the forecast period (2022-2029).

Attention-deficit hyperactivity disorder (ADHD) is a disorder that is marked by an ongoing pattern of hyperactivity-impulsivity and inattention that interferes with functioning or development.

Market Dynamics

The increasing access to health insurance for mental health treatment and rising incidence of ADHD.

The increasing access to health insurance for mental health treatment is expected to drive market growth.

Health insurance is defined as insurance for future surgical or medical expenditures. It is a contract where an individual or group of people by paying a fee called the premium purchase in advance for their health coverage. Based on the type of plan, usually, the insured person is either required to pay for the health expenses from their pocket, which the insurance company then reimburses or the expenses are directly paid by the insurance provider who pays it to the service provider. Data from the National Mental Health Survey (NMHS) reveal that mental disorders are significantly higher in households with lesser income, limited employment, and low levels of education, thus making it evident that they have a greater vulnerability to mental disorders. At the same time, these same factors also limit their access to and utilization of mental health services.

The rising incidence of ADHD is expected to drive market growth.

The prevalence of ADHD is highly variable worldwide, ranging from as low as 1% to nearly 20%, depending on the diagnostic criteria and the assessment tools used. With an estimated worldwide-pooled prevalence of 5.3%, ADHD is the most prevalent mental disorder in children. ADHD (attention-deficit hyperactive disorder) is responsible for 0.06% of total years lost to disability and 0.02% of total DALYs. The majority of the burden due to ADHD occurs in childhood. The magnitude of the burden attributable to ADHD needs the attention of policymakers in terms of early intervention and treatment.

Attention-deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood and adolescence, affecting 2.2 to 17.8% of all school-aged children and adolescents. ADHD in children has been associated with a wide range of developmental deficits, including limitations of learning or control of executive functions and global impairments of social skills.

Side effects associated with ADHD drugs are expected to hamper market growth.

In reducing symptoms of ADHD, stimulant medications can be very effective, but some kids experience uncomfortable or harmful side effects. When side effects become a problem, doctors try to change the dosage, the release formula, or the type of medication a child takes. The goal is to understand what will benefit them with the least side effects. Trouble sleep may also be caused by kids being too stimulated at bedtime, often by doing something on the computer to calm themselves. Their ADHD may keep them awake if the medication has worn off.

Another ADHD medication, atomoxetine (Strattera), isn't a stimulant but has been linked to adults and irregular heartbeats. The FDA suggests people with a history of these problems stay away from others. ADHD drugs may be connected to some mental health issues, but it's rare. For instance, some people have reported behavior problems like aggression and hostility. In contrast, others developed symptoms of bipolar disorder. The FDA also warned that there's a slight risk that stimulant ADHD drugs could lead to symptoms of psychosis-like hearing things or mood swings and paranoia.

COVID-19 Impact Analysis

Due to several protocols, medical practices have been affected during the COVID-19 pandemic. The procedures for diagnosis and monitoring attention deficit hyperactivity disorder (ADHD) problems involved in this pandemic have been affected. As people are scared to undergo therapies for ADHD or even buy the medication due to the risk of COVID-19, there has been an impact on the attention deficit hyperactivity disorder (ADHD) market.

Industry Analysis

The attention-deficit hyperactivity disorder market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Stimulants segment is expected to hold the largest market share in the attention-deficit hyperactivity disorder Market

Stimulants effectively manage ADHD symptoms such as short attention span, impulsive behavior, and hyperactivity. Many stimulants are available: short-acting (immediate-release), intermediate-acting, and long-acting. The commonly used treatment for Attention-Deficit Disorder/ Hyperactivity Disorder is stimulant therapy. Stimulants effectively manage ADHD symptoms such as impulsive behavior, short attention span, and hyperactivity. They may be used alone or in combination with behavior therapy. These drugs improve ADHD symptoms in about 70% of adults and 70% to 80% of children shortly after starting treatment. Improvements include reduced interrupting, fidgeting, and other hyperactive symptoms, home relationships, and improved task completion. Improvements in behavior and attention span usually continue as long as the medication is taken. However, social adjustment and school performance benefits have not yet been shown to endure over the long term.

Currently, the most commonly prescribed medications for ADHD are stimulant drugs (psychostimulants). Stimulants appear to boost and balance levels of brain chemicals called neurotransmitters. These medications help improve the signs and symptoms of inattention and hyperactivity, sometimes in a short period. Amphetamines include dextroamphetamine (Dexedrine),dextroamphetamine-amphetamine, and lisdexamfetamine (Vyvanse). Stimulant drugs are available in long-acting and short-acting forms. A long-acting patch of methylphenidate (Daytrana) is available that can be worn on the hip.

The pediatric and Adolescents segment will dominate the attention deficit hyperactivity disorder (ADHD)

Estimates suggest that about 4% to 12% of children have ADHD. Boys are 2 to 3 times more likely to have ADHD of the hyperactive or combined type than girls. In the U.S, around 6.1 million children (9.4 percent) between the ages of 2 to 17 are estimated to have been diagnosed with attention deficit hyperactivity disorder (ADHD or ADD).

The American Psychiatric Association (APA) stated that 5 % of children in America have ADHD. But the Centers for Disease Control and Prevention (CDC) put the number at more than double the APAs. According to the CDC, 11 percent of American children, ages 4 to 17, have an attention disorder. Approximate 8.4% of children and 2.5% of adults have ADHD. ADHD is first identified in school-aged children when it leads to disruption in the classroom or problems with schoolwork. ADHD from childhood is a chronic health problem with a significant risk for mortality, the persistence of ADHD, and long-term morbidity in adulthood. Though ADHD has been reported to affect 4.4% of adults, the estimation of the persistence of ADHD from childhood to adulthood has varied widely, ranging from 6% to 66.

Retail Pharmacies segment will dominate the attention deficit hyperactivity disorder (ADHD)

Attention-deficit hyperactivity disorder (ADHD) medications are subject to abuse, misuse, and diversion. Obtaining ADHD prescriptions from multiple prescribers or filled across multiple pharmacies, known as 'doctor shopping,' may reflect such unsanctioned use. No clinical guidelines exist to guide dosing or indications for use, making it difficult to have a standardized treatment approach, especially with differing state regulations. Instead of traditional pharmacies, patients seeking marijuana for medicinal use often go to dispensaries. Some dispensaries focus on stocking and selling only recreational or medicinal products, while others offer both.

Retail Pharmacies would be the safest place for dispensing attention-deficit hyperactivity disorder (ADHD) medications. Pharmacists are experts in medication and play a significant role in dispensing and monitoring medication to ensure safe and optimal use. Dispensing, like other ADHD medications, through a pharmacy is the safest option.

Geographical Analysis

North American region is expected to hold the largest market share in the global attention-deficit hyperactivity disorder market.

A behavioral disorder Attention-deficit hyperactivity disorder (ADHD) affects up to 1 in 20 children in the USA. The predominance of American research into this disorder over the past 40 years has led to the impression that ADHD is largely an American disorder and is much less prevalent elsewhere.

ADHD isn't just a childhood disorder. About 4% of American adults over the age of 18 contend with ADHD behaviors daily. In adulthood, it's diagnosed equally between males and females. During their lifetimes, 13% of men will be diagnosed with ADHD, while just 4.2% of women will be diagnosed. Current prevalence rates of ADHD vary between states, with Nevada having the lowest rate at 4.2% and Kentucky having the highest rate of 14.8%. In addition, due to the launch of products by regional players. For instance, Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., received U.S. regulatory approval in March 2019. Food and Drug Administration (FDA) for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII for the treatment of attention deficit hyperactivity disorder (ADHD) in patients six years of age and older. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the attention-deficit hyperactivity disorder market are Pfizer Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, UCB S.A., Hisamitsu Pharmaceutical Co., Inc., Purdue Pharma L.P. and Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.:

Overview:

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for treating central nervous system (CNS) diseases. Their extensive expertise in product development has been built over the past 30 years. Initially as a standalone development organization, then as a U.S. subsidiary of Shire plc is Supernus Pharmaceuticals Inc. They market products in the United States through their specialty sales force and seek strategic collaborations with other pharmaceutical companies to license products outside the United States.

Product Portfolio:

The company is developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Key Development:

The U.S. Food and Drug Administration (FDA) approved Qelbree, the first new non-stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents in more than 10 years. Manufactured by Supernus Pharmaceuticals, Inc. Qelbree (viloxazine extended-release capsules) is a selective norepinephrine reuptake inhibitor-a class of drugs often used to treat anxiety and depression, and sometimes ADHD. Qelbree is approved to treat young people with ADHD between the ages of 6 and 17 years.

The global attention-deficit hyperactivity disorder market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Drug Type
  • 3.2. Market Snippet By Age Group
  • 3.3. Market Snippet By Distribution Channel

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing access to health insurance for mental health treatment
      • 4.1.1.2. The rising incidence of ADHD will drive the attention deficit hyperactivity disorder (ADHD) market
    • 4.1.2. Restraints:
      • 4.1.2.1. Side-effects associated with ADHD drugs will hamper the attention deficit hyperactivity disorder (ADHD) market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. Stimulant*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
  • 7.3. Non-stimulant

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Pediatric and Adolescents*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
  • 8.3. Adults

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Retail Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
  • 9.3. E-Commerce

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch
  • 11.5. List of Company with disruptive technology
  • 11.6. List of Start Up Companies

12. Company Profiles

  • 12.1. Supernus Pharmaceuticals, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Pfizer Inc
  • 12.3. Novartis AG
  • 12.4. Eli Lilly and Company
  • 12.5. GlaxoSmithKline PLC
  • 12.6. Mallinckrodt Pharmaceuticals
  • 12.7. Johnson & Johnson
  • 12.8. Hisamitsu Pharmaceutical Co., Inc.,
  • 12.9. Chongqing Fujin Biology Medical Company
  • 12.10. Wanbang Medical Company LIST NOT EXHAUSTIVE

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us